Company Overview and News

 
Australians developing gold projects in Africa focus on quality of projects

2018-08-29 proactiveinvestors.com.au
Networking by Australian companies developing projects in Africa got underway a day early yesterday at an event in Perth.
GMR CDV CDNL

 
Golden Rim Resources identifies bedrock gold anomalies at Kouri project

2018-08-16 proactiveinvestors.com.au
Golden Rim Resources Ltd (ASX:GMR) has intersected gold-anomalous bedrock during infill auger drilling at its Kouri Gold Project in Burkina Faso.
GMR

 
Three junior explorers raise $12.3m

2018-07-30 businessnews.com.au
Junior explorers Magnetic Resources, Golden Rim Resources and Real Energy will tap investors in separate capital raisings worth a combined $12.3 million.
GMR MAU

 
Golden Rim Resources raising $4 million to advance Kouri Gold Project

2018-07-30 proactiveinvestors.com.au
Golden Rim Resources Ltd (ASX:GMR) has received commitments from institutional and professional investors to raise around $3 million in a placement.
GMR

 
Golden Rim Resources makes its third gold discovery in Burkina Faso

2018-07-18 proactiveinvestors.com.au
Golden Rim Resources (ASX: GMR) is an exploration company which has just made a new gold discovery at its Kouri project in Burkina Faso.
GMR

 
Golden Rim Resources discovers significant gold mineralisation at Burkina Faso project

2018-07-16 proactiveinvestors.com.au
Golden Rim Resources Ltd (ASX:GMR) has discovered two broad zones of mineralisation of up to 7.7 g/t gold at its Red Hill prospect near its 1 million ounce Kouri resource in Burkina Faso.
ASL GMR

 
Golden Rim Resources extends gold mineralisation at Kouri project in Burkina Faso

2018-07-12 proactiveinvestors.com.au
Golden Rim Resources Ltd (ASX:GMR) has extended gold mineralisation at its Kouri project in Burkina Faso with drilling also highlighting the potential for depth extensions.
GMR

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...